PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Chou R, Dana T, Bougatsos C, et al. Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. (Evidence Syntheses, No. 91.)

References

1.
Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(3):192–9. [PubMed: 18678846]
2.
U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185–91. [PubMed: 18678845]
3.
Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(11):917–29. [PubMed: 12458993]
4.
American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010. [19 October 2011]. Accessed at http://www​.cancer.org​/acs/groups/content​/@nho/documents/document/acspc-024113​.pdf.
5.
National Cancer Institute. SEER Stat Fact Sheets: Prostate. Bethesda, MD: National Cancer Institute; 2011. [19 October 2011]. Accessed at http://seer​.cancer.gov​/statfacts/html/prost.html.
6.
U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2007. Incidence and Mortality Web-Based Report. Atlanta: Centers for Disease Control and Prevention; 2010. [19 October 2011]. Accessed at www​.cdc.gov/uscs.
7.
Shao YH, Albertsen PC, Roberts CB, et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/mL. Arch Intern Med. 2010;170(14):1256–60. [PMC free article: PMC3651841] [PubMed: 20660846]
8.
Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2008. Bethesda, MD: National Cancer Institute; 2011. [19 October 2011]. Accessed at http://seer​.cancer.gov​/csr/1975_2008/index.html.
9.
Wilt TJ, Shamliyan T, Taylor B, et al. Comparative Effectiveness of Therapies for Clinically Localized Prostate Pancer, Comparative Effectiveness Review No. 13. Rockville, MD: Agency for Healthcare Research and Quality; 2008. [19 October 2011]. Accessed at http://www​.effectivehealthcare​.ahrq.gov/ehc​/products/9/80/2008​_0204ProstateCancerFinal.pdf.
10.
Stattin P, Holmberg E, Johansson JE, et al. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010;102(13):950–8. [PMC free article: PMC2897875] [PubMed: 20562373]
11.
Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302(15):1685–92. [PubMed: 19843904]
12.
Kirschner-Hermanns R, Jakse G. Quality of life following radical prostatectomy. Crit Rev Oncol Hematol. 2002;43(2):141–51. [PubMed: 12191736]
13.
Imperato-McGinley J, Zhu YS. Androgens and male physiology: the syndrome of 5α-reductase-2 deficiency. Mol Cell Endocrinol. 2002;198(1–2):51–9. [PubMed: 12573814]
14.
Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388–413. [PubMed: 16368524]
15.
Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859–64. [PubMed: 12642065]
16.
Dall’Era MA, Kane CJ. Watchful waiting versus active surveillance: appropriate patient selection. Curr Urol Rep. 2008;9(3):211–6. [PubMed: 18765115]
17.
American Urological Association. Prostate-Specific Antigen Best Practice Statement: 2009 Update. Linthicum, MD: American Urological Association; 2009. [19 October 2011]. Accessed at http://www​.auanet.org​/content/guidelines-and-quality-care​/clinical-guidelines​/main-reports/psa09.pdf.
18.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Fort Washington, PA: National Comprehensive Cancer Network; 2010. [PubMed: 20141680]
19.
Prostate Cancer Canada. Early Detection Guidelines. Toronto, Ontario: Prostate Cancer Canada; 2010. [19 October 2011]. Accessed at http://www​.prostatecancer​.ca/PCCN/Prostate-Cancer​/diagnosis/Early-Detection-Guidelines.aspx.
20.
Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2002;52(1):8–22. [PubMed: 11814067]
21.
Aus G, Abbou CC, Pacik D, et al. EAU guidelines on prostate cancer. Eur Urol. 2001;40(2):97–101. [PubMed: 11528184]
22.
Lim LS, Sherin K. ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men: ACPM position statement on preventive practice. Am J Prev Med. 2008;34(2):164–70. [PubMed: 18201648]
23.
American Academy of Family Physicians. Prostate Cancer. Leawood, KS: American Academy of Family Physicians; 2008. [19 October 2011]. Accessed at http://www​.aafp.org/online​/en/home/clinical​/exam/prostatecancer.html.
24.
Mackie A. Screening for prostate cancer: review against programme appraisal criteria for the U.K. National Screening Committee. London: U.K. National Screening Committee; 2010. [19 October 2011]. Accessed at www​.screening.nhs.uk/policydb_download​.php?doc=78.
25.
National Health Committee of New Zealand. Prostate Cancer Screening in New Zealand. Wellington, New Zealand: National Health Committee; 2004. [19 October 2011]. Accessed at http://www​.nhc.health​.govt.nz/moh.nsf/indexcm​/nhc-prostate-cancer-screening?Open.
26.
Cancer Council Australia. Position Statement: Prostate Cancer Screening. Sydney, Australia: Cancer Council Australia; 2010. [19 October 2011]. Accessed at http://www​.cancer.org​.au/File/PolicyPublications​/Position_statements​/PS_prostate​_cancer_screening_updated_June_2010.pdf.
27.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the third U.S. Preventive Services Task Force. Am J Prev Med. 2001;20(3 Suppl):21–35. [PubMed: 11306229]
28.
National Cancer Institute. Prostate Cancer Treatment (PDQ): Stage Information for Prostate Cancer. Bethesda, MD: National Cancer Institute; 2011. [19 October 2011]. Accessed at http://www​.cancer.gov​/cancertopics/pdq/treatment​/prostate/HealthProfessional​/page3.
29.
Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31. [PubMed: 17509297]
30.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. [PMC free article: PMC192859] [PubMed: 12958120]
31.
Johansson E, Bill-Axelson A, Holmberg L, et al. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol. 2009;55(2):422–30. [PubMed: 18783877]
32.
Fransson P, Damber JE, Tomic R, et al. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer. 2001;92(12):3111–9. [PubMed: 11753990]
33.
Fransson P, Damber JE, Widmark A. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer. Scand J Urol Nephrol. 2009;43(2):119–26. [PubMed: 18985545]
34.
Bill-Axelson A, Holmberg L, Filén F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst. 2008;100(16):1144–54. [PMC free article: PMC2518167] [PubMed: 18695132]
35.
Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708–17. [PubMed: 21542742]
36.
Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977–84. [PubMed: 15888698]
37.
Byar DP, Corle DK. VACURG randomised trial of radical prostatetectomy for stages I and II prostatic cancer. Urology. 1981;17(4 Suppl):7–11. [PubMed: 7010763]
38.
Graversen PH, Nielsen KT, Gasser TC, et al. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer: a fifteen-year follow-up. Urology. 1990;36(6):493–8. [PubMed: 2247914]
39.
Holmberg L, Bill-Axelson A, Garmo H, et al. Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am. 2006;20(4):845–55. [PubMed: 16861118]
40.
Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347(11):781–9. [PubMed: 12226148]
41.
Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate: twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl. 1995;172:65–72. [PubMed: 8578259]
42.
Albertsen PC, Hanley JA, Penson DF, et al. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol. 2007;177(3):932–6. [PubMed: 17296379]
43.
Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Eur Urol. 2010;57(4):631–8. [PubMed: 19299069]
44.
Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173–81. [PMC free article: PMC2645653] [PubMed: 18612114]
45.
Merglen A, Schmidlin F, Fioretta G, et al. Short- and long-term mortality with localized prostate cancer. Arch Intern Med. 2007;167(18):1944–50. [PubMed: 17923593]
46.
Schymura MJ, Kahn AR, German RR, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1) BMC Cancer. 2010;10:152. [PMC free article: PMC2876077] [PubMed: 20403178]
47.
Tewari A, Divine G, Chang P, et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy—a propensity scoring approach. J Urol. 2007;177(3):911–5. [PubMed: 17296374]
48.
Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296(22):2683–93. [PubMed: 17164454]
49.
Zhou EH, Ellis RJ, Cherullo E, et al. Radiotherapy and survival in prostate cancer patients: a population-based study. Int J Radiat Oncol Biol Phys. 2009;73(1):15–23. [PMC free article: PMC2742208] [PubMed: 18538495]
50.
Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347(11):790–6. [PubMed: 12226149]
51.
Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol. 2001;166(5):1804–10. [PubMed: 11586228]
52.
Choo R, Long J, Gray R, et al. Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. Support Care Cancer. 2010;18(6):715–22. [PubMed: 19506916]
53.
Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001;39(10):1118–30. [PubMed: 11567174]
54.
Galbraith ME, Ramirez JM, Pedro LW. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nurs Forum. 2001;28(3):551–60. [PubMed: 11338762]
55.
Hoffman RM, Hunt WC, Gilliland FD, et al. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma: results from the Prostate Cancer Outcomes Study. Cancer. 2003;97(7):1653–62. [PubMed: 12655522]
56.
Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129–35. [PubMed: 7799493]
57.
Litwin MS. Health-related quality of life after treatment for localized prostate cancer. Cancer. 1995;75:2000–3.
58.
Litwin MS, Lubeck DP, Spitalny GM, et al. Mental health in men treated for early stage prostate carcinoma. Cancer. 2002;95(1):54–60. [PubMed: 12115317]
59.
Lubeck DP, Litwin MS, Henning JM, et al. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology. 1999;53:180–6. [PubMed: 9886609]
60.
Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst. 2002;94(6):430–7. [PubMed: 11904315]
61.
Schapira MM, Lawrence WF, Katz DA, et al. Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care. 2001;39(3):243–53. [PubMed: 11242319]
62.
Siegel T, Moul JW, Spevak M, et al. The development of erectile dysfunction in men treated for prostate cancer. J Urol. 2001;165(2):430–5. [PubMed: 11176390]
63.
Smith D, Carvalhal G, Schneider K, et al. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer. 2000;88(6):1454–63. [PubMed: 10717630]
64.
Smith DP, King MT, Egger S, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ. 2009;339:b4817. [PMC free article: PMC2784818] [PubMed: 19945997]
65.
Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21(21):3979–86. [PubMed: 14581420]
66.
Thong MS, Mols F, Kil PJ, et al. Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden. BJU Int. 2009;105(5):652–8. [PubMed: 19747357]
67.
Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst. 2005;97(20):1525–32. [PubMed: 16234566]
68.
Yao SL, Lu-Yao G. Population-based study of relationships between hospital volume of prostatectomies, patient outcomes and length of hospital stay. J Natl Cancer Inst. 1999;91(22):1950–6. [PubMed: 10564679]
69.
Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346(15):1138–4. [PubMed: 11948274]
70.
Walz J, Montorsi F, Jeldres C, et al. The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases. BJU Int. 2008;101(7):826–32. [PubMed: 18321316]
71.
Augustin H, Hammerer P, Graefen M, et al. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur Urol. 2003;43(2):113–8. [PubMed: 12565767]
72.
Rabbani F, Yunis LH, Pinochet R, et al. Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy. Eur Urol. 2010;57(3):371–86. [PubMed: 19945779]
73.
Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology. 2004;63(2):297–300. [PubMed: 14972475]
74.
Blana A, Rogenhofer S, Ganzer R, et al. Eight years’ experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology. 2008;72(6):1329–33. [PubMed: 18829078]
75.
Muto S, Yoshii T, Saito K, et al. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol. 2008;38(3):192–9. [PubMed: 18281309]
76.
Thüroff S, Chaussy C, Vallancien G, et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European Multicentric Study. J Endourol. 2003;17(8):673–7. [PubMed: 14622488]
77.
Uchida T, Ohkusa H, Nagata Y, et al. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int. 2006;97(1):56–61. [PubMed: 16336329]
78.
Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index: development, reliability and validity of a health-related quality of life measure. Med Care. 1998;36(7):1002–12. [PubMed: 9674618]
79.
Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46. [PMC free article: PMC3107568] [PubMed: 19996060]
80.
Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56. [PubMed: 16983113]
81.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64. [PubMed: 15647578]
82.
Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493–500. [PubMed: 17657815]
83.
Tsai HK, D’Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516–24. [PubMed: 17925537]
84.
Shelley M, Wilt TJ, Coles B, Mason MD. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev. 2007;(3):CD005010. [PubMed: 17636783]
85.
Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst. 2009;101(19):1325–9. [PMC free article: PMC2758309] [PubMed: 19720969]
86.
Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in the primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117–23. [PMC free article: PMC2834465] [PubMed: 20124165]
87.
Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer: a SEER analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(1):58–68. [PubMed: 18374503]
88.
Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol. 2008;180(5):2005–9. [PubMed: 18801517]
89.
Chou R, Aronson N, Atkins D, et al. AHRQ Series Paper 4: assessing harms when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2010;63(5):502–12. [PubMed: 18823754]
90.
Zerbib M, Zelefsky MJ, Higano CS, Carroll PR. Conventional treatments of localized prostate cancer. Urology. 2008;72(6 Suppl):S25–35. [PubMed: 19095125]
91.
Zelefsky MJ, Moughan J, Owen J, et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care Survey for prostate cancer. Int J Radiation Oncology Biol Phys. 2004;59(4):1053–61. [PubMed: 15234039]
92.
Marberger M, Carroll PR, Zelefsky MJ, et al. New treatments for localized prostate cancer. Urology. 2008;72(6 Suppl):S36–43. [PubMed: 19095127]
93.
Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30(1):81–7. [PubMed: 18783735]
94.
Edge SB, Byrd DR, Compton CC, et al., editors. AJCC Cancer Staging Manual. 7. New York: Springer; 2010. pp. 457–68.
95.
van As NJ, Parker CC. Active surveillance with selective radical treatment for localized prostate cancer. Cancer J. 2007;13(5):289–94. [PubMed: 17921727]
96.
Zoorob R, Anderson R, Cefalu C, Sidani M. Cancer screening guidelines. Am Fam Physician. 2001;63(6):1101–12. [PubMed: 11277547]
97.
Ito K, Kakehi Y, Naito S, et al. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol. 2008;15(9):763–8. [PubMed: 18786203]
Cover of Treatments for Localized Prostate Cancer
Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation [Internet].
Evidence Syntheses, No. 91.
Chou R, Dana T, Bougatsos C, et al.

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...